CloneID: MLTA3698A (Pateclizumab)
Heavy Chain modification: Fc Silent™
Antigen Long Description: This humanized antibody was derived from a mouse anti-human LT-α hybridoma mAb.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P01374
Specificity Statement: This antibody is specific for lymphotoxin-alpha, and is able to bind both the soluble LTα3 homotrimeric form and the cell-surface LTα1β2 heterotrimer, which is transiently expressed on activated B and T cells (Th1, Th17).
Application Notes (Clone): This antibody has been shown to able to both block LTα-mediated signaling and selectively deplete LTα-expressing activated T and B cells, which has therapeutic applications in abrogating proinflammatory responses in rheumatoid arthritis (RA) pathology (Kennedy, 2014). Preliminary clinical trials demonstrated that administration of this antibody decreased serum levels of CXCL13, a biomarker of RA disease activity (Emu, 2012). In a phase II trial, this antibody had a trend for clinical effects on the symptoms of RA after 3 months of treatment, but the differences from placebo responses were not statistically significant (Kennedy, 2014). In a human peripheral blood mononuclear cell transplanted SCID mouse model of graft-versus-host disease, this antibody specifically depleted activated LTα-expressing human donor T and B cells, prolonging survival of the mice (Chiang, 2012). Finally, this antibody has been used to in FC and surface plasmon resonance analysis to characterise its interaction with the LTα ligand.